HopeStage
Back to all studies
CompletedNCT02505984

Nasal Oxytocin to Prevent Postpartum Depression and Anxiety

About this titleRead the official source — NCT02505984
Medication studyAges 18–50United States
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 50 years.

Listed locations
BostonSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: January 2016
Recruitment status
Completed
Enrollment listed in the registry
56
Sponsor
Massachusetts General Hospital
Sponsor type
Hospital / academic medical center
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United States
Age range
From 18 Years to 50 Years
Official registry ID
NCT02505984
Official title
Show the full official title

Testing the Efficacy of Intranasal Oxytocin for the Prevention of Postpartum Depression and PTSD

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Massachusetts General Hospital, a hospital or academic medical center.

Did this study involve medication?

Yes. The study involved medication, including Oxytocin and Placebo.

Who was this study for?

Listed age limits: 18 years to 50 years.

Want to explore more studies?

Explore studies